Bayer/Onyx's Nexavar fails Phase III melanoma trial
This article was originally published in Scrip
Executive Summary
Bayer/Onyx Pharmaceutical's multi-targeted kidney and liver cancer drug Nexavar (sorafenib) has failed a first-line Phase III trial in advanced melanoma in combination with chemotherapy, which could spell the end of the drug for this difficult-to-treat disease.